Abstract: Hepatitis type C (HC) is a common infectious disease and there are more than 170 million people worldwide infected with hepatitis type C virus (HCV), which is a serious threat to human health. With the increasing prevalence of cancer, the anti-cancer therapies are renewed day by day. HCV reactivation after anti-cancer therapy is an issue not to be neglected. It may cause hepatic injury in varying degrees, and its effect on the prognosis, prophylactic strategies and optimal treatments are still being researched.